NCT00750256

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects

A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects

Conditions

• Anaemia

Interventions

Type	Name	Description
DRUG	GSK1278863A	GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.

Timeline

• Start date: 2008-07-07
• Primary completion: 2008-12-12
• Completion: 2008-12-12
• First posted: 2008-09-10
• Last updated: 2017-07-21

Locations

1 site across 1 country: United States